Universal Beteiligungs und Servicegesellschaft mbH Purchases 111,941 Shares of Organon & Co. $OGN

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Organon by 27.1%, buying 111,941 shares to own 525,423 shares (about 0.20% of the company) worth roughly $3.77 million at quarter-end.
• Organon is facing a proposed $14 per share cash deal with Sun Pharma that pushed the stock to 52‑week highs and prompted analyst target upgrades, but law firms have launched investigations into the fairness of the sale process.
• Organon missed Q4 estimates with EPS of $0.63 vs. $0.73 expected and revenue of $1.51B vs. $1.52B (down 5.3% year-over-year); the company pays a modest dividend with a current yield of about 0.6%.

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Organon & Co. (NYSE:OGN - Free Report) by 27.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 525,423 shares of the company's stock after purchasing an additional 111,941 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.20% of Organon & Co. worth $3,767,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Foster Dykema Cabot & Partners LLC bought a new stake in shares of Organon & Co. during the 3rd quarter valued at $29,000. Rothschild Investment LLC lifted its position in shares of Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock valued at $42,000 after acquiring an additional 1,646 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock valued at $31,000 after acquiring an additional 2,033 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Organon & Co. by 70.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company's stock valued at $53,000 after acquiring an additional 2,109 shares during the period. Finally, Hantz Financial Services Inc. lifted its position in shares of Organon & Co. by 188.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 7,702 shares of the company's stock valued at $82,000 after acquiring an additional 5,028 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Price Performance

Shares of OGN stock opened at $13.34 on Thursday. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.38. The company has a market cap of $3.50 billion, a P/E ratio of 18.79, a P/E/G ratio of 1.22 and a beta of 0.67. The business has a fifty day simple moving average of $7.57 and a 200 day simple moving average of $7.72.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the prior year, the company earned $0.90 earnings per share. Organon & Co.'s quarterly revenue was down 5.3% compared to the same quarter last year. On average, sell-side analysts forecast that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, February 23rd. Organon & Co.'s dividend payout ratio is currently 11.27%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on OGN shares. Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and upped their target price for the company from $5.00 to $14.00 in a research report on Tuesday. BNP Paribas Exane reiterated a "neutral" rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research report on Wednesday. Barclays upped their target price on Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research report on Tuesday, February 24th. Zacks Research upgraded Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. Finally, Wall Street Zen downgraded Organon & Co. from a "buy" rating to a "hold" rating in a research report on Saturday, January 31st. Four investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Reduce" and an average target price of $11.40.

Key Headlines Impacting Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma deal and cash consideration provide a clear floor (shareholders to receive $14.00 per share), lifting M&A bidders’ enthusiasm and pushing the stock to 52-week highs. Organon & Co. (OGN) Soars to 52-Week High on $11.75-Billion Sun Merger
• Positive Sentiment: Piper Sandler upgraded OGN from underweight to neutral and set a $14.00 price target, signaling dealer support for the transaction price and narrowing downside risk. Piper Sandler upgrade
• Neutral Sentiment: Organon canceled its Q1 earnings call because of the announced agreement with Sun Pharma — a procedural step reflecting the pending deal rather than new operational news. Organon Cancels First Quarter Earnings Call
• Neutral Sentiment: BNP Paribas Exane reaffirmed a neutral rating and raised its price target to $14.00 (up from $12.00), aligning the street around the deal price while stopping short of a buy endorsement. BNP Paribas Exane reaffirmation
• Negative Sentiment: Law firms (Kahn Swick & Foti and Halper Sadeh) have launched investigations into whether the $14.00 cash price and the sale process are fair to shareholders — these inquiries can lead to litigation, potential delays, or renegotiation. Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon Co. - OGN
• Negative Sentiment: BNP Paribas Exane previously moved OGN from strong‑buy to hold (coverage adjustment), signaling reduced enthusiasm from a formerly bullish analyst and potentially limiting further upside absent a competing bidder or higher offer. Analyst downgrade

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.